Nutra Pharma Announces Svizera Labs to Supply Designer Diagnostics' Test Kits to the World Health Organization
April 2, 2006 (Press Release) --
BOYNTON BEACH, Fla.-- March 31, 2006 -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, and Svizera Labs have agreed in principal to supply Designer Diagnostics' Test Kits to the World Health Organization (WHO). Svizera will begin distribution of the kits after completion of a series of required testing and analysis. Svizera is currently the exclusive provider of tuberculosis test kits to WHO. Svizera also provides 60% of the antibiotics for the treatment of tuberculosis to WHO.
"The planned partnership with Svizera is an incredible opportunity for Designer Diagnostics. It will allow us to distribute our diagnostic test kits directly where they are needed most," explained Neil Roth, President of Designer Diagnostics. "We expect distribution as soon as the testing and analysis requirements for WHO are met and then to grow the distribution levels dramatically over the next twelve months," he concluded.
In 2005, Svizera distributed over 15 million diagnostic test kits to WHO. Details of the Designer Diagnostics agreement include replacing the current tuberculosis diagnostic test kits being distributed by Svizera with the introduction of the Designer Diagnostics NTM Test Kit and antibiotic sensitivity kits.
About SVIZERA
Svizera is a globally owned brand by Maneesh Pharmaceuticals Pvt. Ltd. The Company specializes in the marketing and distribution of products for the treatment of tuberculosis throughout India. Svizera is currently the exclusive supplier of diagnostic test kits to the World Health Organization.
http://www.maneeshpharma.com/
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp., through its subsidiaries, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
"The planned partnership with Svizera is an incredible opportunity for Designer Diagnostics. It will allow us to distribute our diagnostic test kits directly where they are needed most," explained Neil Roth, President of Designer Diagnostics. "We expect distribution as soon as the testing and analysis requirements for WHO are met and then to grow the distribution levels dramatically over the next twelve months," he concluded.
In 2005, Svizera distributed over 15 million diagnostic test kits to WHO. Details of the Designer Diagnostics agreement include replacing the current tuberculosis diagnostic test kits being distributed by Svizera with the introduction of the Designer Diagnostics NTM Test Kit and antibiotic sensitivity kits.
About SVIZERA
Svizera is a globally owned brand by Maneesh Pharmaceuticals Pvt. Ltd. The Company specializes in the marketing and distribution of products for the treatment of tuberculosis throughout India. Svizera is currently the exclusive supplier of diagnostic test kits to the World Health Organization.
http://www.maneeshpharma.com/
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp., through its subsidiaries, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
Email
Print
SPAM
